Sanara MedTech Stock: Balance Sheet and Debt
SMTISanara MedTech has a debt to equity ratio of 8.13 and an interest coverage of 0.9x. Since the end of 2023 debt has exceeded cash, at the end of 2022 it was the other way round.
Daily figure as of 20 Nov 2026
Balance Sheet Over Time
At the end of 2022 cash still exceeded debt by $8.14M. In 2022 Sanara MedTech spent $2.52M on acquisitions, and goodwill and intangible assets rose from $4.73M to $35.11M. Goodwill and intangible assets equal 375% of equity. On paper, Sanara MedTech would need 15 years of free cash flow like 2025 to pay off net debt of $31.61M.
Total Assets and Equity Ratio
How large the balance sheet of Sanara MedTech Inc. is, how much of it is equity and how much is goodwill from acquisitions.
Equity ratio
Figures as a table
| Year | Total assets | Goodwill and intangible assets | of which goodwill | Equity ratio | Net debt |
|---|---|---|---|---|---|
| 2006 | $496.29K | not reported separately | not reported separately | −256.1% | $1.04M |
| 2007 | $405.73K | not reported separately | not reported separately | −447.0% | $1.51M |
| 2008 | $151.71K | not reported separately | not reported separately | −211.8% | $1.51M |
| 2009 | $4.77M | $4.58M | not split out | 48.5% | $1.37M |
| 2010 | $6.78M | $4.11M | not split out | 42.3% | $2.53M |
| 2011 | $3.83M | $432.68K | not split out | −100.7% | $1.36M |
| 2012 | $1.39M | $344.46K | not split out | −273.1% | $2.37M |
| 2013 | $977.15K | $293.43K | not split out | −252.6% | $1.54M |
| 2014 | $1.5M | $242.4K | not split out | −55.1% | $1.08M |
| 2015 | $1.39M | $191.37K | not split out | −91.3% | $1.64M |
| 2016 | $2.17M | $140.34K | not split out | −19.5% | $784.62K |
| 2017 | $2.22M | $117.29K | not split out | 4.6% | $736.81K |
| 2018 | $3.04M | $52.27K | not split out | 36.6% | $768.15K |
| 2019 | $11.12M | $1.47M | not split out | 57.5% | −$4.51M |
| 2020 | $9.83M | $3.1M | not split out | 59.4% | $26.02K |
| 2021 | $36.4M | $4.73M | not split out | 82.8% | −$18.23M |
| 2022 | $61.04M | $35.11M | $3.6M | 68.4% | −$8.14M |
| 2023 | $73.87M | $48.53M | $3.6M | 60.4% | $6.64M |
| 2024 | $88.09M | $44.61M | $3.6M | 44.2% | $16.41M |
| 2025 | $72.94M | $22.24M | $3.6M | 8.1% | $31.61M |
The equity ratio divides total equity, including non-controlling interests, by total assets. Net debt is debt minus cash and short-term investments; a negative figure means cash exceeds debt. In years without separate goodwill, the table shows the sum of goodwill and intangible assets, because the data do not list goodwill separately there.
Equity and Debt
What the Company Owns and Owes
- Cash & equivalents
- Equity
- Debt
Figures as a table
| Year | Cash & equivalents | Equity | Debt | Debt / Equity |
|---|---|---|---|---|
| 2006 | $236.3K | −$1.27M | $1.28M | −1.01 |
| 2007 | $781 | −$1.81M | $1.51M | −0.83 |
| 2008 | $1.14K | −$321.26K | $1.51M | −4.69 |
| 2009 | −$4.36K | $2.31M | $1.37M | 0.59 |
| 2010 | $50.84K | $2.87M | $2.58M | 0.9 |
| 2011 | $3.61K | −$3.86M | $1.37M | −0.35 |
| 2012 | $45.86K | −$3.81M | $2.42M | −0.64 |
| 2013 | $44.55K | −$2.47M | $1.58M | −0.64 |
| 2014 | $523.44K | −$825.4K | $1.61M | −1.95 |
| 2015 | $182.34K | −$1.27M | $1.82M | −1.43 |
| 2016 | $833.48K | −$423.07K | $1.62M | −3.82 |
| 2017 | $463.19K | $102.54K | $1.2M | 11.7 |
| 2018 | $731.85K | $1.11M | $1.5M | 1.35 |
| 2019 | $6.61M | $6.61M | $2.1M | 0.33 |
| 2020 | $455.37K | $6.15M | $481.38K | 0.08 |
| 2021 | $18.65M | $30.64M | $425.44K | 0.01 |
| 2022 | $8.96M | $41.83M | $819.22K | 0.02 |
| 2023 | $5.15M | $44.83M | $11.79M | 0.26 |
| 2024 | $15.88M | $39.4M | $32.29M | 0.83 |
| 2025 | $16.58M | $5.93M | $48.19M | 8.13 |
Debt to equity divides debt by total equity, including non-controlling interests, as S&P calculates it. The equity column shows the part that belongs to shareholders.
Debt of Industry Peers
Sanara MedTech's debt to equity is higher than that of 40 of 40 other stocks in the Medical (Instruments & Supplies) industry.
| Stock | Debt to equity | Equity ratio |
|---|---|---|
| Kestra Medical Technologies | 0.18 | 72.4% |
| STAAR Surgical | 0.11 | 76.2% |
| Gerresheimer | 1.45 | 24.6% |
| Safilo Group | 0.24 | 53.1% |
| Dynavox Group | 1.83 | 24.3% |
| AngioDynamics | 0.07 | 63.9% |
| Embecta | no data | no data |
| COLTENE Holding | 0.47 | 54.4% |
| Sanara MedTech | 8.13 | 8.1% |
Figures from the latest fiscal year. The eight peers closest in market value, largest first.
Data and Required Disclosures
- ; time horizon around 12 months
- Rated Neutral since 7 Nov 2026; valuation signal Fairly valued since 17 Nov 2026
- Price: closing price of 19 Nov 2026
- Data from Financial Modeling Prep (FMP) based on the company's reports, latest fiscal year 2025. MEQIRI calculates the score and fair value itself every night.
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.
